MD A33: Deciphering placental cytokine and immune cell responses in pemphigoid gestationis

Pemphigoid gestationis (PG) is a rare autoimmune blistering disease occurring in the second or third trimester of pregnancy or postpartum. It is characterized by severe pruritus and polymorphic inflammatory skin lesions. In addition to cutaneous manifestations, PG is associated with an increased risk of adverse pregnancy outcomes, including preterm labor, hypertensive disorders of pregnancy, gestational diabetes, and fetal growth restriction.
Previous studies indicate that anti-BP180 autoantibodies can bind to placental structures and may trigger local inflammatory responses. However, the molecular and cellular mechanisms initiating placental inflammation remain poorly understood.
Thus, this project aims to elucidate how maternal anti-BP180 autoantibodies contribute to placental inflammation and dysfunction. Specifically, the project will investigate antibody-induced cytokine responses in placental cells and explants and characterize immune cell populations in placental tissue from patients with PG.
The results will provide mechanistic insights into the placental pathology of PG and may help determine whether early or targeted immunosuppressive therapy could reduce the risk of adverse pregnancy outcomes. Ultimately, these findings may contribute to more precise and individualized clinical management strategies for patients with PG.